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Abstract 
Background: During the last decades, there have been many different opinions concerning the neurocognitive 
function in Bipolar disorder (BD). The aim of the current study was to perform a systematic review of the literature and 
to synthesize the data in a comprehensive picture of the neurocognitive dysfunction in BD.
Methods: Papers were located with searches in PubMed/MEDLINE, through June 1st 2015. The review followed 
a modified version of the recommendations of the Preferred Items for Reporting of Systematic Reviews and Meta-
Analyses statement.
Results: The initial search returned 110,403 papers. After the deletion of duplicates, 11,771 papers remained for fur-
ther evaluation. Eventually, 250 were included in the analysis.
Conclusion: The current review supports the presence of a neurocognitive deficit in BD, in almost all neurocognitive 
domains. This deficit is qualitative similar to that observed in schizophrenia but it is less severe. There are no differ-
ences between BD subtypes. Its origin is unclear. It seems it is an enduring component and represents a core primary 
characteristic of the illness, rather than being secondary to the mood state or medication. This core deficit is con-
founded (either increased or attenuated) by the disease phase, specific personal characteristics of the patients (age, 
gender, education, etc.), current symptomatology and its treatment (especially psychotic features) and long-term 
course and long-term exposure to medication, psychiatric and somatic comorbidity and alcohol and/or substance 
abuse.
© 2015 Tsitsipa and Fountoulakis. This article is distributed under the terms of the Creative Commons Attribution 4.0 Interna-
tional License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in 
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-
mons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecom-
mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The neurocognitive dysfunction in BD has been the 
focus of debate for many years. It was not clear whether 
the observed neurocognitive deficit could be explained 
by iatrogenic or alcohol and/or drug abuse effects or by 
the temporary functional changes which constitute the 
result of mood changes. Also, it was unclear whether 
the impairment is the product of degenerative structural 
brain changes or of some kind of structural changes of a 
neurodevelopmental origin (trait), or it is secondary to 
mood dysregulation (state). Recent data suggested that 
the neurocognitive deficit is not only an enduring com-
ponent of the illness, but also represents a core primary 
characteristic of the illness, rather than being second-
ary to the mood state or medication [1]. It has been sug-
gested by recent data that 84 % of patients suffering from 
schizophrenia, 58.3  % of psychotic major depressive 
patients, and 57.7 % of psychotic BD patients are neuro-
cognitively impaired (at least one SD below healthy con-
trols in at least two domains) [2].
It has also been suggested that patients with BD are 
more creative (e.g., artists, scientists, etc.) and have 
higher IQ in comparison to the general population [3–7]. 
However, more recent data reported a significant and 
broad neurocognitive deficit, which seems to be present 
even before the first manifestation of mood symptoms, 
and it persists across the different phases and even wors-
ens during the course of the illness [8–13]. Several stud-
ies suggest that 40 % of BD patients are impaired in one 
neurocognitive domain, one-third or more are impaired 
in at least two neurocognitive domains and 22 % in three 
or more domains [14, 15]. This deficit is rather stable and 
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relatively independent from mood changes, probably 
reflecting trait features of BD [16–19] Even after control-
ling for confounding variables, such as education and 
social class and clinical symptoms, it has been indicated 
that the neurocognitive impairment in BD is less pro-
nounced in comparison to that in schizophrenia [20, 21].
Gender, age, education, phase of the illness and medi-
cation status constitute some of the identified confound-
ing factors. Additionally, patients in a severe depression 
or mania cannot be tested.
A significant limitation in this kind of research is that 
the performance in most tests is influenced by more than 
one neurocognitive process. It is a fact that the bounda-
ries between neurocognitive processes are unclear and 
no process is completely independent from the others. 
Different approaches in their classification and nomen-
clature have been proposed, adding to the confusion. The 
domain of executive functions, particularly, is open to 
several different approaches and conceptualizations.
The aim of the current study was to perform a system-
atic review of the literature to identify all studies pertain-
ing to the topic of neurocognitive dysfunction in BD and 




Reports investigating the neurocognitive dysfunction in 
BD patient samples were located with searches in Pub-
med/MEDLINE, through June 1st 2015. Only reports in 
English language were included.
The Pubmed database was searched using the search 
terms ‘Bipolar’ OR ‘Mania’ OR ‘manic’ OR ‘Manic-
depression’ OR Manic-depressive AND ‘Neurocogni-
tion’ OR ‘Neurocognitive’ OR ‘Neuropsychology’ OR 
‘Neuropsychological’ OR ‘Cognitive’ OR ‘Cognition’ 
OR ‘Intelligence quotient’ OR ‘IQ’ OR ‘VIQ’ OR ‘PIQ’ 
OR ‘North American Adult Reading Test’ OR ‘NAART’ 
OR ‘wide Range Achievement Test’ OR ‘WRAT’ OR 
‘Wechsler Adult Intelligence Scale’ OR ‘WAIS’ OR 
‘Mental speed’ OR ‘Digit Symbol Substitution Test’ OR 
‘DSST’ OR ‘Trail Making Test’ OR ‘TMT’ OR ‘Reaction 
time’ OR ‘Attention’ OR ‘Attentional’ OR ‘Vigilance’ OR 
‘Concentration’ OR ‘Continuous Performance Test’ OR 
‘CPT’ OR ‘Digits Forward’ OR ‘Learning’ OR ‘Memory’ 
OR ‘Working memory’ OR ‘Declarative memory’ OR 
‘Verbal memory’ OR ‘Non-verbal memory’ OR ‘Visual 
memory’ OR ‘Logical memory’ OR ‘Autobiographi-
cal memory’ OR ‘Prospective memory’ OR ‘Immediate 
memory’ OR ‘Delayed memory’ OR ‘Verbal learning’ 
OR ‘Digits Backward’ OR ‘California Verbal Learn-
ing Test’ OR ‘CVLT’ OR ‘Rey Auditory Verbal Learn-
ing Test’ OR ‘RAVLT’ OR ‘Wechsler Memory Scale’ OR 
‘WMS’ OR ‘Free recall’ OR ‘Rey Complex Figure Test’ 
OR ‘RCFT’ OR ‘Verbal skills’ OR ‘Verbal fluency’ OR 
‘Category fluency’ OR ‘Letter fluency’ OR ‘Controlled 
Oral Word Association Test’ OR ‘COWA-FAS’ OR ‘Ani-
mal Naming’ OR ‘Visuospatial’ OR ‘Constructional’ OR 
‘Block design’ OR ‘Rey Complex Figure Test’ OR ‘RCFT’ 
OR ‘Clock test’ OR ‘Executive function’ OR ‘Reason-
ing’ OR ‘Inhibitory control’ OR ‘Executive control’ OR 
‘Concept formation’ OR ‘Wisconsin Card Sorting Test’ 
OR ‘WCST’ OR ‘Stroop Color Word Test’ OR ‘Stroop’ 
OR ‘SCWT’ OR ‘Theory of Mind’ OR ‘ToM’ OR ‘Emo-
tion processing’ OR ‘Emotional decision-making’ OR 
‘Benton Facial Recognition Test’ OR ‘BFRT’ OR ‘Faces 
Test’ OR ‘Eyes Test’ OR ‘Hinting Task’ OR ‘False belief 
and deception’ OR ‘Picture sequencing’ OR ‘Character 
intention’ OR ‘Faux Pas’.
Only papers in English language were included.
This review followed a modified version of the rec-
ommendations of the Preferred Items for Reporting of 
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment [22].
Results
The initial search returned 110,403 papers. Αfter the 
deletion of duplicates 11,771 remained. The reference 
lists of review papers and books were scanned and even-
tually and after assessing these papers on the basis of 
title and abstract 250 papers remained for further study 
(Fig. 1).
A list of neurocognitive domains and the neuropsycho-
logical tools usually used for their assessment are shown 
in Table 1.
General neurocognitive functioning and Intelligence quotient 
(IQ)
It has been reported that both patients with BD and their 
families have above average IQ and general intellectual 
functioning [23–29], or at least they have intelligence 
similar to healthy controls [30–34]. On the other hand, 
higher functioning and preserved neurocognitive per-
formance during the premorbid phase, as well as higher 
social class could push towards a mood disorders diagno-
sis rather than schizophrenia [25, 30, 34–45].
Overall, the literature reports that patients with BD 
manifest moderate global reduction in their neurocogni-
tive functioning as reflected in their IQ scores and their 
performance in neuropsychological batteries, irrespec-
tive of illness phase [43, 44, 46–48]. It has also been 
shown that these deficits are milder but may be qualita-
tively similar to those seen in patients with schizophrenia 
[21, 49]. The impairment is more severe in the presence 
of psychotic features [50], and, in line with this, it has 
been suggested that the deficit is comparable to that seen 
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in schizophrenia, especially during the acute psychotic 
manic phase [51–54].
One study suggested the presence of a more com-
plex relationship between BD and IQ since it has been 
reported that although BD was related to higher premor-
bid IQ, further analysis revealed that men with the lowest 
and the highest IQ (especially verbal or practical ability) 
were at the greatest risk for pure BD (without comorbid-
ity) [55]. There are inconclusive data concerning whether 
psychotic BD is related to impaired premorbid IQ [56, 
57].
It is well known that the full IQ is composed of two 
composite scores; the Verbal IQ (VIQ) and the non-ver-
bal or Performance IQ (PIQ). The effect size of the deficit 
during the manic phase is 0.06 and 0.28 for PIQ and VIQ, 
respectively [53]. It seems that during acute mania the 
effect size is equal to 0.47 for the full IQ [54]. There are 
no studies concerning the IQ in patients during the acute 
depressive phase. Since it is possible, the premorbid IQ of 
BD patients is higher in comparison to the normal popu-
lation, the true magnitude of decline cannot be evaluated 
accurately, and all studies reporting this decline in com-
parison to population norms underestimate it.
According to a meta-analysis, patients with BD show 
higher VIQ in comparison to PIQ scores [58, 59]. This 
is due to the uniform reduction in all PIQ subtest scores 
with an accompanying preservation of VIQ scores. This 
impairment is not because of the slowing in mental speed 
which is observed in BD patients (since four PIQ subtests 
in comparison to one VIQ subtest are timed) and this 
is obvious from the quality of the deficit which persists 
during periods of euthymia, and it is confirmed from tar-
geted research [60]. The deficit might be already present 
during the early stages of BD [61] although more recent 
data argue against this [62]. One study has reported that 
the severity of depression seems to reduce VIQ scores 
and thus it might diminish the VIQ-PIQ discrepancy 
[63]. It is important to notice that this discrepancy does 
not seem to be present in patients with unipolar depres-
sion [64].
It has been reported that the VIQ-PIQ discrepancy 
might reflect a specific effect of BD on ‘fluid intelligence’ 
(the capacity to think logically and solve problems in 
novel situations, independently of acquired knowledge) 
with a simultaneous respect of the ‘crystallized intel-
ligence’ (the ability to use skills, knowledge, and experi-
ence; it does rely on long-term memory). However, any 
attempt for a deep understanding of this deficit is risky 
and premature [63].
When all phases of the illness are taken into consid-
eration, the effect sizes concerning current IQ reduction 
range from 0.36 to 070 [63, 65]. For patients in remission, 
the results of meta-analyses are inconclusive. The effect 
sizes reported for PIQ range from 0.40 to 0.50 [63, 66] 
to lower and within the normal range, that is 0.11–0.16 
[8, 12]. A problem is that most meta-analyses report an 
effect size for the full IQ and not separately for VIQ and 
PIQ. The effect size of premorbid IQ change in euthymic 
BD patients is reported to be low and not significant 
(0.04–0.20) [66, 67].
Psychomotor and mental speed
Although mental speed and psychomotor activation are 
two concepts which overlap and include reaction time, 
cognitive and motor speed and, manual dexterity, they 
are clearly not identical. Additionally, most of the neu-
ropsychological tools which are used for the evaluation 
of psychomotor and mental speed also assess other neu-
rocognitive functions, and this is at least partially a con-
sequence of a methodology effect, because to measure 
‘speed’, you need to initiate a ‘procedure’ whose ‘speed’ is 
going to be measured.
It has been reported that the reaction time in bipolar 
depressive patients is prolonged [68]. Also, euthymic 
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Fig. 1 The PRISMA flowchart
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patients had not only prolonged reaction times but also 
more error rates in a visual backward masking test. Over-
all, reaction time prolongation has been found to be asso-
ciated with burden of illness and especially past history 
of depressions but not with current medication [69].
Irrespective of illness phase and symptom severity, 
the speed of mental processing in BD patients seems to 
be slower [34, 43–45, 59, 70–87]. Moreover, it has been 
reported that the speed of mental processing is less 
affected in comparison to schizophrenia [38, 40, 61, 88], 
although there are some data suggesting the presence of 
a similar degree of impairment between patients with BD 
and patients with schizophrenia [89]. On the other hand, 
it has been suggested that there were no significant dif-
ferences between depressed BD patients, euthymic BD 
patients and healthy controls in psychomotor speed [90]. 
Another study suggested that patients with BD showed 
a linear improvement in processing speed in the first 
year after resolution of their initial manic episode [91]. 
It has been reported that bipolar depressives manifest 
slower mental speed in comparison to manic and uni-
polar depressives, even after corrected for motor speed. 
The interesting feature in that particular study was that 
distraction improved the mental speed of BD depressed 
patients while it adversely influenced the speed of the 
other two groups [92].
The deficit could be present already during the early 
stages of BD [93]. Individual studies suggested that the 
magnitude of mental speed impairment in patients with 
BD is reported to correspond to an effect size of 0.82–1.08 
[48, 77, 94]. When all phases of the illness are taken into 
consideration, the effect size 0.50–0.55 (which is similar 
to that observed concerning the IQ) [63, 65]. In euthymic 
BD patients, one meta-analysis reported that the effect 
size with the use of the TMT-A was 0.52 and with the 
DSST was 0.59 [13]. A second study reported effect sizes 
of 0.60 and 0.79, respectively [67], a third one reported 
effect sizes equal to 0.64 and 0.76 [12], a fourth 0.71 and 
0.84 [8] and a fifth 0.7 and 07–0.8, respectively [66].
It is important to note that the deficit in the process-
ing speed might have a significant confounding effect 
on the performance in almost all neurocognitive testing 
and controlling for it might make any difference between 
groups concerning other neurocognitive domains dis-
appear [95]. Also, it is suggested that global functional 
impairment is strongly associated with poor performance 
on a cognitive measure of processing speed (e.g., WAIS 
Digit Symbol or the TMT) [75, 96].
Table 1 Neurocognitive domains assessed in the literature and neuropsychological tools used
Domain Tool
Premorbid IQ Single-word reading score from the North American Adult Reading Test (NAART)
Wide Range Achievement Test (WRAT)
Vocabulary subtest score from the Wechsler Adult Intelligence Scale (WAIS)
Current IQ Wechsler Adult Intelligence Scale (WAIS)
Psychomotor and mental speed Digit Symbol Substitution Test (DSST)
Trail Making Test-A (TMT-A)
Reaction time tests
Attention Continuous Performance Test (CPT)
Digits forward
Working memory Digits backward
Verbal memory
 Learning California Verbal Learning Test (CVLT)
 Short delayed recall Rey Auditory Verbal Learning Test (RAVLT)
 Long delayed recall Wechsler Memory Scale-Logical Memory (WMS-LM)
 Recognition Free recall
Non-verbal Memory Rey Complex Figure Test (RCFT)—Immediate and delayed recall
Wechsler Memory Scale-Visual Reproduction (WMS-VR)
Visuospatial function Block design
Rey Complex Figure Test (RCFT)-copy
Language/verbal fluency Controlled Oral Word Association Test (COWA-FAS)
Animal naming (AN)
Executive function Wisconsin Card Sorting Test (WCST)—categories achieved and perseverative errors
Stroop Color Word Test (SCWT)
Trail Making Test-B (TMT-B)
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Attention
Attention is a concept that includes a number of pro-
cesses which work together, influence one another or 
prerequisite one another. These processes are: work-
ing memory (which refers to the ability to keep a lim-
ited number of mental objects in awareness for a limited 
duration of time), vigilance (which is the capacity to iden-
tify a specific target among many other stimuli), freedom 
from distraction or interference and the ability to split or 
to rapidly shift attention. Concentration is a term which 
refers to the ability to sustain attention over prolonged 
periods of time. There are many tests, with each of them 
assessing one of the previously mentioned processes. For 
example, the Continuous Performance Test assesses vigi-
lance while ‘span tasks’ assess working memory. How-
ever, all these tests except from the specific aspect of 
attention they assess are also influenced from the other 
processes which are related to attention as well. Working 
memory is often classified as belonging to the executive 
functions and it is often considered in relation to them.
The magnitude of the attentional impairment is inde-
pendent of current symptomatology and of the phase of 
the illness; however, significant variability is present in 
the literature [34, 44, 48, 71, 85, 87, 91, 97–113]. It has 
been also reported that the impairment is present already 
during the early stages of the disorder [93] and it is less 
pronounced in comparison to the deficit seen in patients 
with schizophrenia [38, 114, 115]. On the other hand, 
however, some studies reported that there is a similar 
magnitude of impairment between patient with BD and 
patients with schizophrenia [89, 116, 117]. It has been 
suggested that the performance in divided attention (DA) 
varied considerable over time within patients. It was also 
found a significant quadratic relationship between manic 
symptoms and DA performance, even after corrected 
for the effect of psychotropic medication. It has been 
suggested that mild hypomanic symptoms have a posi-
tive influence on divided attention scores and moder-
ate to severe manic symptoms have a negative influence. 
No association between depressive symptoms and DA 
performance was found [118]. The magnitude of effect 
sizes ranges from 0.36 to 0.82 [48, 94, 119] depending on 
the domain assessed and the composition of the study 
sample.
The overall effect size calculated after a meta-analysis is 
0.64 which is similar to that reported concerning the rest 
of neurocognitive functions [63]. Another meta-analy-
sis reported that attention is impaired during the acute 
manic/mixed state, with effect sizes ranging from 0.79 
to 0.90, during the acute depressed state with an effect 
size up to 0.80, but also during euthymia with effect size 
from 0.41 to 0.65 [11]. Another meta-analysis concern-
ing BD patients during euthymia has reported medium 
effect sizes (0.48–0.60 depending on the testing condi-
tion) [13], while a third one found effect sizes of similar 
magnitude (0.62 and 0.74 for CPT hits and reaction time, 
respectively) [67]. A fourth meta-analysis gave effect size 
0.58 for CPT and 0.37 for digits forward [8] and a fifth 
reported an effect size equal to 0.8 for CPT [66].
There are also a limited number of studies which indi-
cate no impairment in attention [79, 120–123], and this 
concerns especially euthymic patients [124]. One study 
has found that depressed BD patients, euthymic BD 
patients and healthy controls had no significant differ-
ences in attention [90].
Learning and memory
Learning refers to the ability to acquire and store new 
information. Memory is the mental process that allows 
individuals to retrieve the new information at a later 
time. Learning and memory involve a number of pro-
cesses including attention and concentration, encoding 
and allocation of effort. These processes are distinct from 
one another but interrelated and interdependent. Moreo-
ver, there are different strategies and processes involved, 
depending on whether a short- or a long-term effect is 
desirable and also depending on the quality and nature of 
the information and the frame it is presented in.
A typical classification of learning and memory struc-
ture is shown in Table  2 [125]. Due to the fact that 
much of research on memory is focused on ‘depression’ 
and does not distinguish between unipolar and bipolar 
depression, the results and the conclusions from these 
studies should be received with reservation because it is 
uncertain whether they apply specifically to BD, and to 
which extent.
It has been suggested that there is a deficit in working 
memory [45, 57, 72, 73, 77, 84–87, 126–129] and specifi-
cally in the visuospatial working memory [33, 130–134]. 
Psychotic patients might have worse performance [48, 
135]. The impairment is probably present already since 
the early stages of the illness [136]. Some studies have 
shown that the impairment in working memory affects 
only patients with acute mania [53, 131, 132]. Comparing 
to patients with schizophrenia, the impairment in visuos-
patial working memory is less pronounced [115].
Additionally, there are studies indicating a deficit in 
declarative memory [137] and specifically in the semantic 
[138] and the episodic memory [48, 109, 139, 140], ver-
bal learning [45, 47, 72, 86, 141–147] and this is true both 
for BD-I and BD-II [134, 148]. A deficit is also present 
concerning verbal memory [38, 41, 73, 75, 87, 102, 111, 
143, 144, 147, 149–151], also during periods of euthymia 
[152]. One study, however, has shown that depressed BD 
patients showed greater impairments in verbal memory 
than the euthymic BD patients [90]. It has been suggested 
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that the magnitude of the effect size of the verbal mem-
ory deficit is 0.7–0.9 [41, 139] and it is less pronounced 
in comparison to that seen in schizophrenia [153, 154] 
and cannot be explained by the attentional deficit [120]. 
Patients at early stages of BD have better performance in 
the total immediate free recall and in delayed free recall 
compared to patients at a later stage and to patients 
with schizophrenia. Additionally, concerning the ability 
to retain words learned, BD patients at a later stage and 
chronic patients with schizophrenia were more impaired 
than BD patients at early stage and patients with recent 
onset schizophrenia [155]. It has been also indicated that 
delayed free recall is worse in patients with BD compared 
to healthy controls [156].
There are impairments in total learning as well as 
short- and long-delay verbal recall, recognition, dis-
criminability and learning slope [157], associative learn-
ing [158], implicit motor learning [159], immediate 
memory [134], delayed memory [34, 45, 72, 77, 84, 85, 
94, 108, 160], non-verbal memory [161], visual memory 
[38, 43, 44, 74, 79, 102, 108, 111], autobiographical [162, 
163] and prospective memory [164]. It has been shown 
that prospective memory deficits [165] and short-term 
non-affective memory [166] are also present in remitted 
BD patients suggesting that they constitute a trait deficit. 
Moreover, it has been shown that BD patients manifest a 
deficit in incidental contextual memory in the absence of 
a binding cue at encoding. There was no difference found 
between the groups for contextual memory even under 
incidental encoding with the binding cue. One study has 
indicated that the impairment in the contextual memory 
was reduced by providing cognitive support at encoding 
[167].
There are also negative studies concerning the pres-
ence of impairment in working memory [168–170], spa-
tial working memory [171] and in verbal learning [138] 
and verbal [123, 172, 173] and visual memory [173]. One 
study has shown that the ability to learn is maintained 
both by BD patients and by patients with schizophrenia 
[155] and another study has reported that there were no 
differences between BD patients and healthy controls in 
terms of their slope of learning, retrieval index, retention 
percentage, semantic or serial clustering, errors, or level 
of retrieval [174]. It seems that most memory impair-
ments are due to the presence of confounding variables 
except maybe for verbal recall [101]. The possibility that 
Table 2 Effect sizes concerning the various neurocognitive domains during different phases of BD as well as in high-risk 
relatives (endophenotypes)
The range of values reflects heterogeneity in study samples but also heterogeneity because of the different neuropsychological tools used




 Premorbid IQ Normal Normal
 Current IQ 0.36–0.70 028–0.47 0.11–0.50 0.20
Psychomotor and mental speed 0.50–0.55 0.52–0.80 0.17–022
Attention 0.64 0.79–0.90 0.80 0.41–0.80 0.18–0.36
Memory
 Working memory 0.60 0.54–1.02
 Verbal memory
  Immediate 0.43 0.73–0.82 0.33–0.42
  Delayed 0.34 1.05 1.20 0.71–0.85 0.27–0.33
  Verbal learning 0.91 1.43 0.66–0.90 0.28
 Non-Verbal memory
  Immediate 0.26 0.73
  Delayed 0.51 0.62–0.80 0.13
 Episodic memory 0.62
Visuospatial function 0.65 022–0.57
Language/verbal fluency 0.63 0.51–0.59 0.93 0.34–0.90 0.27
Executive function 0.34–0.79 0.64–0.72 0.54-0.75 0.52–0.88 0.24–0.51
Social cognition
 ToM 0.75–0.86
 Emotion recognition 0.35
 Emotion decision-making Normal
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difficulties in the semantic clustering or other strategic 
processing deficits are the cause for the verbal memory 
impairment has both positive [139, 160] and negative 
data [137, 139, 161, 175].
In meta-analytic studies, when all phases of the illness 
are taken into consideration, the magnitude of the effect 
size is 0.60 for working memory, 0.43 for immediate ver-
bal memory and 0.34 for delayed, 0.26 for immediate vis-
ual memory and 0.51 for delayed [65]. The meta-analysis 
of short-term memory studies revealed an effect size of 
0.58 when span tasks were utilized, without any dif-
ference between auditory or visual tasks. When verbal 
learning tasks were used, the effect size was 0.91 [63].
During the acute manic/mixed state, the magnitude of 
the effect sizes was 1.43 for verbal learning and 1.05 for 
delayed free verbal recall. Additionally, concerning the 
acute depressed state, the effect size for verbal memory 
was 1.20, while during euthymia the domains impaired 
were working memory (0.65), verbal learning (0.81), 
long-delay verbal free recall (0.78), immediate non-verbal 
memory (0.73) and delayed non-verbal recall (0.80) [11].
The average effect size for episodic memory in 
euthymic BD patients is reported to be equal to 0.62 
and for working memory equal to 0.60 [12]. Again 
in euthymic BD patients, a large effect size (0.90) is 
reported for verbal learning and working memory (0.98) 
and somewhat lower effect sizes for aspects of imme-
diate (0.73) and delayed (0.71) verbal memory [13]. A 
third meta-analysis reported effect sizes of 0.81, 0.54, 
0.74 and 0.72, respectively [67]. Another meta-analysis 
reported an effect size of 1.02 for working memory. 0.85 
for delayed recall, 0.82 for immediate recall and 0.62 for 
visual memory [8]. Finally, a last meta-analysis gave an 
effect size of 0.85 for verbal learning, and 0.73 for verbal 
memory-early recall [9, 66]. It seems there is a publica-
tion bias especially concerning verbal learning and after 
correction for this, the effect size is attenuated (from 0.85 
down to 0.66) [9].
Overall, the literature suggests that BD, irrespective of 
illness phase, is characterized by a severe deficit in the 
acquisition of new information, but not in the retention 
[41, 63, 161, 175, 176]. In spite of some opposing data, the 
most probable interpretation which derives from empiri-
cal studies is that the attention and concentration deficits 
impair the acquisition of information and learning, by 
disrupting the engagement of effortful processing which 
results in a shallow rather than deeper level of processing 
(e.g., acoustic rather than semantic) [137, 175, 177–186].
Verbal skills
The evaluation of verbal skills includes mostly the eval-
uation of verbal fluency. Although the literature has 
reported that verbal skills are impaired during all phases 
of BD [84, 87, 108, 129, 147, 149, 166, 169, 187–189], 
there are some studies reporting that this impairment is 
not present during euthymia [41, 52] or during the first 
mood episode [121]. One study has indicated that there 
are errors in speech during the acute manic state, and 
these errors are independent from the co-existence of an 
attentional deficit [106].
Concerning the magnitude of the effect size, it has 
been reported that it is small [169] and even smaller in 
comparison to the effect size that seen in schizophrenia 
[61], however, patients with psychotic BD have a higher 
effect size (0.68–1.73) [94, 117, 190]. Even smaller (below 
0.50) effect sizes have been reported [63], while when 
all phases of the illness are taken into consideration, an 
effect size equal to 0.63 emerges [65]. Both letter flu-
ency and semantic fluency are impaired during the acute 
manic/mixed state and the effect sizes are equal to 0.51 
and 0.59, respectively. The phonemic fluency is impaired 
during the acute depressed state with an effect size equal 
to 0.93 while during euthymia impaired are both pho-
nemic fluency (0.51), and semantic verbal fluency (0.75) 
[11]. In euthymic BD patients, the average effect size for 
verbal fluency ranges between 0.56 and 0.90 [12, 67] but 
it is smaller (0.34) for verbal fluency by letter [13].
Visuospatial skills
The evaluation of visuospatial skills is usually made with 
the use of the complex Rey figure or with the WAIS-R 
block design. Patients with BD and their unaffected rela-
tives show impairment in the visuospatial/constructional 
abilities [45, 147, 191] and in visual learning and mem-
ory [191, 192]. It is interesting that euthymic BD patients 
and patients with schizophrenia have similar impairment 
when the results are controlled for possible confound-
ing factors [193]. Also, one study has shown that BD 
patients were significantly impaired on all three object 
location memory processes (positional memory, object-
location binding, and a combined process), with the larg-
est effect found in exact positional memory (d  =  1.18) 
[194]. Unaffected relatives demonstrated an intermediate 
level of performance in comparison to patients with BD 
and to normal controls [195]. Contrawise, one study sug-
gested that the visual motion integration is intact in BD 
patients [196]. Some authors suggest that the impairment 
in visuospatial skills is restricted in the acute phase while 
these skills might not be affected during remission [41, 
63]. One study has reported that the overall effect size is 
equal to 0.65 [63] and other studies have reported that in 
remitted patients the effect size is 0.22–0.57 [8, 12].
Executive function
The executive system is considered to be involved in the 
planning, the decision-making, the error correction and 
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the troubleshooting, in  situations where responses are 
not well rehearsed or contain novel sequences of actions, 
are dangerous or constitute technically difficult situa-
tions or situations requiring the overcoming of a strong 
habitual response or resisting temptation. In other words, 
‘Controlling of mental and neurocognitive processes’ 
seems to be the key phrase describing the role of execu-
tive functions. In patients with BD, reasoning should be 
considered separately from the rest executive functions 
due to the fact that it seems to rely heavily on verbal and 
linguistic skills [63].
It has been suggested a severe impairment in executive 
functions except reasoning during all phases of BD [34, 
36, 43–45, 48, 70, 72, 73, 75–77, 86, 87, 90, 94, 101–103, 
108, 109, 111, 120–122, 129, 143, 146, 149, 190, 195, 
197–209] and early during the course of BD [93], but the 
deficit is less pronounced in comparison to schizophre-
nia [38, 40, 61, 89, 116, 122, 210]. However, at least a sub-
group of patients is as severely impaired as patients with 
schizophrenia [153, 211, 212]. One study indicates that 
the depressed BD patients showed greater impairments 
in executive functions comparing to the euthymic BD 
patients [90]. It is suggested that this impairment might 
be particularly severe concerning interference and inhibi-
tory control [47, 80, 82, 108, 168, 190, 192, 213–215]. 
Additionally, patients with BD might have more risky 
[216] or erratic choices [217, 218] especially when a his-
tory of alcohol abuse exists [219].
However, not all data are straightforward. Normal 
overall executive function has been suggested by one 
study [144], while another reported only prolonged time 
to complete the test [207]. Also, a bimodal distribution 
of the Wisconsin Card Sorting Test (WCST) scores in 
patients with BD is reported, with some patients at near-
control levels and others significantly impaired [41]. 
According to another study, the performance on the 
executive function measures is bimodal among euthymic 
BD patients (one subgroup with relatively normal and 
one subgroup with impaired executive functioning) [41]. 
Some authors argue that there is no difference between 
BD patients and controls in executive functions [78, 
123, 170, 188, 220, 221], while others argue that the defi-
cit is present only in the more severe and chronic cases 
[188]. It has been also indicated that BD patients show an 
improvement in the executive functions in the first year 
after resolution of their initial manic episode [91].
The deficit in executive functions might be overall 
independent from illness phase, however, there are data 
suggesting that some aspects of the deficit are related to 
affective lability [222], duration of illness, residual mood 
symptoms and current antipsychotic treatment [197] 
and history of psychosis [48]. One study found that the 
impairment in executive function was related to the 
severity of general psychopathology as it is measured by 
the PANSS [198] and another one correlated impaired 
insight with impaired executive functions [223].
A meta-analysis suggested that when taking all phases 
of the illness together, the effect size of this impairment is 
equal to 0.79 when reasoning (which was reported to be 
intact) is excluded [63]. Moreover, another meta-analysis 
reported an effect size of 0.34 for concept formation and 
of 0.55 for executive control, with no significant effect for 
current clinical condition [65]. During the acute manic/
mixed state, the general executive function and the 
speeded set-shifting are impaired with the magnitude of 
effect sizes to be equal to 0.72 and to 0.64, respectively. 
During the acute depressed state, speeded set-shifting is 
impaired (0.64) while during euthymia problem-solving 
tasks (0.54), set-switching tasks (0.73) and verbal inter-
ference (0.75) are impaired [11]. Three recent meta-ana-
lytic studies in euthymic patients reported that the effect 
sizes were for executive functioning equal to 0.80 for the 
TMT-B, 0.56 for the WCST and 0.80 for the Stroop test 
[12] according to the first one, 0.78, 0.62 and 0.63, respec-
tively, according to the second one [13] and 0.55, 0.69 
and 0.71, respectively, according to a third meta-analysis 
[67]. Another meta-analysis reported an effect size of 
0.99 for the TMT-B and 0.88 for the WCST persevera-
tive errors and 0.52 for the WCST categories, 0.73 for the 
Stroop time and 0.65 for the stroop-correct [8]. Similarly, 
another study reported 0.70 for the WCST perseveration 
score and 0.8 for the TMT-B and the stroop test [9, 66].
Social cognition and theory of mind (ToM)
The term ‘social cognition’ constitutes a psychological 
domain with several dimensions. It refers not only to the 
ability of the person to assume that other people have 
minds similar to his/her own and to interpret, but also to 
understand and predict the emotions, desires, intentions, 
behaviors and speech of others (including non-verbal 
elements). Social cognition shapes communication and 
interaction with others and in this way enabling adaptive 
social adaptation. It involves a complex set of processes 
including the representation of internal somatic states, 
knowledge about the self, perception of others, and inter-
personal motivations [224].
The broad theory of mind (ToM) includes three main 
processes (a narrow definition of ToM, emotion process-
ing, and affective decision-making). The narrow defini-
tion of ToM (mentalizing or mindreading) refers to the 
ability to attribute mental states (e.g., beliefs, desires, and 
intents) to oneself and to others. Emotion processing is 
the ability to identify and discriminate basic emotions. 
Affective decision-making is crucial for an appropri-
ate social behavior, and concerns weighing up choices in 
association with reward and punishment [225].
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The tests which are used to evaluate these domains are 
both verbal (scenarios) and non-verbal (pictures). They 
demand the subject to identify and comprehend the situ-
ation, the roles and the interactions and to make appro-
priate planning. So far, empirical data have confirmed 
the universality of facial emotions. This means that the 
specific ability to process and identify facial emotions is 
a substantial feature of human communication and social 
interaction, which is independent of culture. It has been 
found, even in “ecological” tests that mimic real life sce-
narios that patients with BD showed less impairment on 
neurocognitive performance compared to patients with 
schizophrenia [154].
ToM It has been shown that here is a deficit concerning 
ToM and social cognition during all phases of BD [162, 
201, 216, 226–232], although there are also negative stud-
ies [233, 234]. It is possible that after controlling for medi-
cation and other confounding factors, the performance 
of patients is the same with the performance of controls 
[231]. There is also evidence that the impairment in ToM 
is restricted to the acute phases of the illness even when 
memory was controlled for [134] and thus there is no 
impairment during remission [235]. Moreover, patients 
with BD with psychotic features and patients with schizo-
phrenia were found to be equally impaired in their scores 
for ToM stories. However, patients with schizophrenia 
manifested a worse performance [154, 236]. Another study 
reported no impairment in the accuracy of responses, 
but only the presence of a prolonged latency time for the 
response [237].
Generally, the literature supports the presence of a 
robust deficit in ToM in BD patients [78, 216, 232, 238–
241]. This, in spite of one study which has shown that 
there are subtle deficits [229] and a second one which 
has reported no deficit at all [242]. Probably, the impair-
ment in ToM in BD is associated with mood symptoms 
and it might reflect more fundamental underlying neuro-
cognitive deficits rather than representing a specific trait 
marker of the disorder [134].
Emotion processing There are inconclusive data con-
cerning the recognition of emotions in BD patients. On 
one hand, there are studies indicating an impairment in 
emotion recognition, and in the identification and dis-
crimination of emotions even during remission [193, 
209, 229, 231, 240, 242–251]; on the other hand, how-
ever, there are studies reporting no impairment in these 
domains, especially after controlling for medication and 
other confounding variables [78, 231, 238, 239, 252–257].
Patients with BD I, seem to be more impaired in com-
parison to controls on face emotional recognition (FER) 
fear subtests, happiness, on the surprise test and on FER 
total scores [209]. It has been also reported that patients 
with BD do not have any impairment in face recogni-
tion in general, but the impairment exists specifically 
in the facial affect labeling, even during euthymia [246, 
258]. Maybe specific phases affect specific emotions. For 
instance, in acute mania, the recognition of fear and dis-
gust is reported to be impaired [247] while during euthy-
mia patients recognize disgust better [259]. Reduced 
biases in the emotion recognition are related with acute 
bipolar depression while on the contrary increased biases 
in emotion recognition are related with acute mania 
[260]. This mood-congruent bias is state rather than trait 
and contributes as a core characteristic [245, 258, 261]. 
Younger BD participants performed worse than expected 
relative to healthy comparison participants of similar age. 
The deficits were found both concerning child and adult 
faces and were particularly strong for angry child faces, 
which were most often undertaken as sad. The results of 
this particular study were not influenced by medications, 
comorbidities/substance use, or mood state/global func-
tioning [262].
Emotional decision‑making The literature reports that 
there is little or no difference between patients with BD 
and controls on the emotional decision-making compo-
nent [207, 216, 218, 231].
Reviews and meta‑analyses One meta-analysis reported 
an effect size concerning ToM equal to 0.75–0.86 and con-
cerning emotion processing equal to 0.35. The same anal-
ysis found that there was no difference between patients 
with BD and healthy controls concerning the emotional 
decision-making. That specific meta-analysis suggested 
that the performance in ToM and in emotion recognition 
was not associated with years of education, age, sex, dura-
tion of illness, and medication [225].
The significant heterogeneity in the results may be due 
to the differences among studies. These differences con-
cern the neuropsychological tools used and the study 
samples. The specific tests might play a significant role 
since the performance of BD patients might be similar 
to controls in some aspects of emotion recognition but 
other aspects could be impaired or not, depending on the 
clinical state. For example, it has been found that stable 
BD patients might exhibit impaired facial emotion dis-
crimination [193], while on the contrary the depressed 
BD patients’ performance could be similar to healthy 
controls in the perception of chimeric faces. In contrast, 
manic patients might perceive all chimeric faces as posi-
tive [263]. It is interesting that patients might outperform 
normal controls in specific domains (e.g., euthymic BD 
patients in the recognition of disgust) [259]. Depressed 
BD patients might show impairment only in the most 
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difficult tasks [248]. It is important to be noted, however, 
that the effect of the clinical state is controversial since 
it is not consistent across studies [201, 216]. An addi-
tional problem is the fact that these are highly sophisti-
cated neurocognitive functions and depend on the intact 
performance of lower ones; for example, the recogni-
tion of facial affect requires a compilation of attentional, 
executive and emotional abilities. Thus, it is difficult to 
be determined where exactly is the impairment located 
within these mechanisms [249].
In this frame, it is interesting that it has been found 
not only that the impairment in ToM is independent of 
other neurocognitive dysfunctions [201, 244] but also 
that this impairment is unrelated to a history of psy-
chotic symptoms [227]. Of course, there are data sup-
porting the opposite opinion as well, which seems more 
reasonable. Even in euthymic BD, executive dysfunc-
tion and some other neurocognitive impairments such 
as basic emotion recognition might be at least partially 
responsible for the impairment in ToM and social cog-
nition tests [228].
A number of factor have been identified as contribut-
ing to of confounding the deficit. Low level of education 
and family history of BD might predict this impairment 
[216]. Moreover, the perception of emotion may be 
affected by the use of psychotropic medication and par-
ticularly by the use of benzodiazepines and both use and 
non-use of antidepressants. In healthy subjects, benzodi-
azepines impair the recognition of anger, citalopram and 
reboxetine reduce the perception of negative expressions 
and propranolol increases the reaction time to recognize 
sadness [216, 258].
Conclusively, although the available data suffer from 
significant methodological drawbacks, the literature sug-
gests that there is an impairment in ToM in patients with 
BD [264]. Additionally, the theory that the deficit in emo-
tional recognition occurs due to an impairment located 
in right hemisphere does not seem to be strong or suf-
ficient [265] and any neurobiological dysfunction is likely 
to be state-dependent [266]
Clinical correlations
Neuropsychological dysfunction in BD may also be 
related to the clinical symptom pattern and severity, and 
it has been correlated with age, earlier age at onset, medi-
cation status, as well as with idiosyncratic factors affect-
ing the long-term course.
The effect of  medication Medication constitutes an 
important confounding variable when comparing the dif-
ferent phases of BD. Some acutely ill patients might be 
medication-free during testing, however, this is not the 
case with patients in remission. As a result, medication 
status not only constitutes a confounding variable which 
is difficult to control for, but also might introduce a bias 
towards the detection of a deficit, especially in patients 
in remission. On the other hand, however, patients with 
severe mania or severe depression cannot be tested and 
are rarely off medication. Medication could be a possi-
ble reason why patients with BD have poor performance 
on certain neurocognitive tasks. This is in accord with 
the traditional concept that BD is considered to belong 
to the ‘functional psychoses’. According to this approach, 
the attentional impairment is considered to be the core 
neurocognitive deficit and the cause of all other deficits in 
neurocognition.
Overall, medication is considered to be an important 
factor, especially given also the possible neuroprotec-
tive or neurotoxic effect of several agents. For example, 
while most authors argue that lithium is neuroprotective, 
there is a possible neurotoxic effect in the long term, even 
at therapeutic levels, especially when it is prescribed in 
combination with antipsychotics [267].
It is of prime importance to differentiate the neurocog-
nitive deficit caused by the illness itself and the deficit 
which could be medication induced. This differentiation 
determines not only the long-term therapeutical design 
but also the overall outcome. Moreover, such a differen-
tiation requires a comprehensive assessment, on the basis 
of knowledge of those neurocognitive domains which are 
most affected by specific medication agents [268].
Patients under lithium often report that lithium inhib-
its their productivity and creativity [269]. There is no 
specific reason for this although it has been shown that 
lithium reduces unusual associations, and this could be 
the possible underlying mechanism [269]. On the other 
hand, however, it is not clear whether this constitutes a 
true deficit or it reflects a subjective feeling as a conse-
quence of the transition from the manic/hypomanic to 
the euthymic state. It should be noted that this loss of 
creativity might be specifically related to lithium and not 
to divalproex [270].
Additionally, it seems that lithium has a negative 
impact on neurocognition especially on memory and 
psychomotor functioning [271–275] but fortunately 
the insult does not seem to be cumulative [276]. More 
specifically, it has been found that lithium impairs both 
mental and motor speed, short-term memory, and ver-
bal or associative fluency, but the impairment is revers-
ible when lithium is withdrawn and re-establishes when 
lithium is re-administered [272, 277, 278]. Lithium also 
causes a deficit in the long-term recall (retrieval) with-
out having an effect on attention or on encoding [271, 
278–281]. This impairment might especially concern 
verbal memory [94, 282]. Fortunately, it has been shown 
that cognitive complaints do not seem to be significant 
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predictors of discontinuation of lithium treatment [283, 
284].
There are limited data which disagree with the sug-
gestion that lithium causes a significant neurocognitive 
impairment [285]. These data especially argue that lith-
ium has no adverse effect on the reaction time [69] and 
executive functions [221]. Moreover, a longitudinal study 
found no evidence for a neurocognitive deterioration 
over a 6-year period in a sample of BD patients treated 
with lithium [276].
Overall, it seems that the effect size of the neurocogni-
tive deficit related to lithium treatment is small and equal 
to 0.30 [8]. This is especially true concerning immediate 
verbal learning and memory (0.24), creativity (0.33) and 
psychomotor speed (0.62). Delayed verbal memory, vis-
ual memory, attention and executive function might not 
be affected at all [286].
The data on the possible deleterious effect of antipsy-
chotics and antiepileptics on neurocognition are rare and 
conflicting [268, 287, 288]. Valproate and carbamazepine 
might cause an impairment in attention [289]. Topira-
mate, which is an agent which is not used in the treat-
ment of BD per se, but is often administered in patients 
to treat a comorbid substance abuse disorder or to lose 
weight, impairs verbal memory, attention, causes psycho-
motor slowing, and impairs word finding even at very low 
dosages (25–50  mg/day). This deficit is reversible after 
discontinuation of the drug [277, 290].
In general, neuroleptics cause impairment in sustained 
attention and in visuomotor speed [291]. Moreover, even 
after controlling for clinical features, current antipsy-
chotic treatment is related to worse performance across 
all executive function tests as well as in verbal learning 
and recognition memory and in semantic fluency in BD 
patients [41, 197, 292]. One study did not find any adverse 
effects concerning risperidone [293]. While another one 
suggested that years of exposure to antipsychotic medi-
cation were related to the impairment in executive func-
tions [108]. It is unclear whether this deficit constitutes a 
true medication adverse effect or it is the consequence of 
the manifestation of psychotic symptoms, for the treat-
ment of which, antipsychotics were prescribed.
Overall, it has been shown that medications have a lim-
ited adverse effect on neurocognitive function [294] if 
any at all [295–297]. On the contrary, there seems to be a 
close relationship between poor treatment adherence and 
neurocognitive impairment, but the causal inferences of 
these findings are uncertain. It is unclear whether it is the 
poor treatment adherence which leads to a worse neuro-
cognitive performance through worsening of the overall 
course of BD, or, on the contrary, it is the neurocognitive 
impairment which causes poor treatment adherence and 
reflects a more severe form of the illness [298].
It is known that patients with BD are often treated with 
benzodiazepines which interfere with memory [299]. 
Also, some patients are treated with complex combina-
tions of lithium, antipsychotics, antiepileptics, antide-
pressants, and benzodiazepines, and the combinatorial 
effects of these drugs on neurocognition are a matter of 
speculation rather than research.
Medication probably causes some degree of neuro-
cognitive deficit particularly in sustained attention and 
in psychomotor speed [9]. It is difficult to differentiate 
this impairment from the impairment caused by the ill-
ness per se. It has been reported by studies compar-
ing euthymic patients with or without medication that 
there are little effects of medication on neurocognitive 
test performance [104, 300]. It has also been mentioned 
that patients which were assessed during their first epi-
sode, thus before any exposure to medication drugs, also 
showed a neurocognitive impairment that was more or 
less similar, to the impairment observed in chronically 
medicated patients [301]. However, there is one study 
which reported that medicated BD-II patients performed 
worse in sustained attention than unmedicated BD-II 
patients [287].
In those individuals with full inter-episode remission 
doing well off medication, this adverse effect might be 
obvious, however it is also well known that staying off 
medication will adversely affect the overall course of the 
illness. It is unfortunate that no currently known phar-
macotherapy improves neurocognition in BD substan-
tially. Preliminary findings suggest some potential value 
for adjunctive stimulants such as modafinil and novel 
experimental agents [268].
The effect of psychotic symptoms It has been shown that 
the presence of psychotic symptoms is strongly related 
to a worse overall neurocognitive performance [48, 57, 
83, 84, 94, 100, 108, 129, 190, 227, 302–307] and in psy-
chotic BD patients various aspects of the neurocognitive 
impairment are similar in magnitude to those observed in 
patients with schizophrenia [85, 133, 307]. Some negative 
studies exist as well [66, 77, 190, 227] and they suggest that 
the deficit in BD is overall less pronounced in comparison 
with schizophrenia. However, in several neurocognitive 
domains such as working memory and executive func-
tion, the deficit is similar to that seen in schizophrenia 
although as a general profile the neurocognitive deficit in 
psychotic BD patients is similar to that seen in unipolar 
psychotic depression [66].
A meta-analysis reported that patients with BD per-
form better than patients with schizophrenia, and the 
effect sizes of the difference varied between 0.26 and 0.63 
for IQ, mental speed, verbal working memory, immediate 
visual memory, verbal fluency (with had the largest effect 
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size equal to 0.63), executive control, and concept forma-
tion, but without any difference concerning the rest of 
domains [65]. It is important to note that there were only 
quantitative, and not qualitative, differences. Significant 
heterogeneity in effect sizes was present between studies, 
and this was partially due to the methodological issues 
and the size and clinical characteristics of the study sam-
ples [307].
Even in the absence of current psychotic symptoms, a 
history of psychotic features is also strongly related to a 
worse neurocognitive performance [129, 188], especially 
concerning measures of executive functioning, verbal and 
spatial working memory [48, 84]. However, it does not 
seem to exist a complete categorical distinction between 
psychotic and non-psychotic BD since this effect is mod-
est [308]. The presence of family history correlates with 
a worse visuomotor attention in psychotic BD patients 
[309]; however, this load is less severe in comparison 
with schizophrenia since the offspring of mothers with 
BD has less neurocognitive impairment in comparison 
to offspring of mothers with schizophrenia [310]. Prob-
ably depending on the study sample (proportion of BD-I 
and BD-II patients) and the definition of psychosis, the 
results vary, and are suggestive of a nosological contin-
uum between psychotic and non-psychotic bipolar cases. 
It is interesting that such a history of psychotic symptoms 
is inversely related to the neurocognitive function in the 
patients’ relatives [311].
Another meta-analysis reported that between patients 
with and without a history of psychotic symptoms, there 
were no differences concerning attention and visual 
memory. The observed differences in global IQ, mental 
speed, working memory, planning and reasoning and 
executive functions are small and only after excluding 
one outlier study [227], the effect size in the executive 
functions increases to 0.55 [308].
It is possible that the neurocognitive differences 
between psychotic and non-psychotic BD patients are 
in fact the result of an earlier onset of illness or medica-
tion use rather than a result of psychosis per se. In accord 
with this, one meta-analysis of cases suggested that psy-
chotic BD patients in the above studies had a younger age 
of illness onset, more hospital admissions and a larger 
proportion of them were using antipsychotics. Also, they 
had lower education [308].
Schizoaffective patients perform poorer in a global 
way, maybe because current psychotic symptoms or his-
tory of psychosis is related to more severe neurocogni-
tive impairment no matter the specific diagnosis [83, 129, 
312]. Euthymic and stabilized schizoaffective patients are 
reported to perform worse than BD patients in attention, 
concentration, declarative memory, executive function, 
and perceptuomotor function [312, 313]
The effect of mood symptoms Data are not available for 
very severely manic or depressed patients because most 
of these patients cannot be tested. Additionally, extrapo-
lating conclusions on these patients from the study of less 
severe cases is problematic.
The overall severity of mood symptoms might not 
affect memory performance at least in those patients 
whose neurocognitive functions can be assessed [175]. 
There are studies showing no effect of either acute 
phase on the neurocognition of patients with BD [71, 
142]. However, the bulk of the literature suggests that 
acute mania is associated to impulse control [314] and 
executive function impairments [315]. Acute bipolar 
depression is related with an attentional bias [287] with 
lowering of mental speed and impaired attention in gen-
eral [100, 316]. There is also a verbal fluency [71], ver-
bal recall and fine motor skills deficit [101]. It has been 
found impaired performance on theory of mind tests in 
both acutely depressed and manic patients, even when 
memory was controlled for [235]. The fluctuation in 
both manic and depressive symptoms have an appreci-
able impact on neurocognitive functioning [11]. While 
moderate changes in affective symptoms did not co-vary 
with neurocognitive ability [317] when changes are more 
severe or when rapid-cycling emerges, there is neurocog-
nitive dysfunction [318].
It has been shown by a number of research stud-
ies and meta-analyses that in many domains there is a 
severe neurocognitive deficit even during remission [8, 
9, 66, 307, 319], although there are also studies which 
keep some reservations [235, 320]. One meta-analysis 
showed that the illness phase had no effect on the short-
term memory deficit [63] and some authors indicate that 
the consequence of antipsychotic therapy alone might 
be responsible for the impairment observed during the 
euthymic phase [292].
The data concerning the impairment in executive func-
tions are inconclusive since there are studies suggesting 
that the deficit is independent from illness phase, how-
ever, there are reports indicating that some aspects of it 
are related to affective lability [222], duration of illness, 
residual mood symptoms, current antipsychotic treat-
ment [197] and history of psychosis [48]. A relationship 
between the impairment in executive function with the 
severity of general psychopathology as it is measured by 
the PANSS [198] and with impaired insight have been 
reported [223]. Finally, differences in the neurocognitive 
performance could be the result of differences in somatic 
comorbidity (and co-medication) between BD patients 
and normal controls [321].
An important methodological problem is that the 
definition criteria for euthymia differ among studies 
and as a result, conclusions are suspect. Maybe even 
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subsyndromal conditions might affect verbal memory 
[120] and also the presence of residual mood symptoms, 
regardless of polarity, might have a negative impact, on 
measures of attentional interference [197]. The impair-
ment in ideation fluency is associated with residual 
mania, but not depression [285]. Our picture concerning 
the presence of the neurocognitive deficit during euthy-
mia might change after controlling for residual symptoms 
in stabilized euthymic patients [19, 97, 192].
One study reported that apart from current symptoma-
tology, the number of previous hospitalizations and family 
history of mood disorder are associated with the impair-
ment in memory in patients with BD [137]. Particularly, 
the impairment in verbal memory might relate to the 
presence of subsyndromal mood symptoms, the duration 
of illness and the numbers of previous manic episodes, 
suicide attempts and hospitalizations [120, 144, 149].
The first follow-up study found that from patients with-
out any neurocognitive impairment at first episode, one-
third had significant deficits after 5–7  years [322]. The 
overall picture could be more complex since during the 
first episode of the illness, in non-psychotic patients, there 
might be no neurocognitive deficits at all, while, patients 
with psychotic features manifest a deficit comparable to 
that seen in patients with schizophrenia [302]. After the 
first episode, the time to recover was associated with exec-
utive function and possibly with verbal fluency [323].
A meta-analysis confirmed that neurocognitive impair-
ment is present during all phases of BD. That meta-
analysis calculated the respected effect sizes for specific 
neurocognitive domains separately for each phase. Dur-
ing the acute manic/mixed states, these effect sizes 
showed a clear impairment in attention (0.79–0.90), ver-
bal learning (1.43) and delayed free verbal recall (1.05), 
letter fluency (0.51) and semantic fluency (0.59), general 
executive function (0.72) and speeded set-shifting (0.64). 
During acute bipolar depression, there were impairments 
in attention (0.80), verbal memory (1.20), phonemic flu-
ency (0.93) and executive function in speeded set-shift-
ing (0.64). During the euthymic phase, these effect sizes 
showed a clear impairment in auditory (0.41) and sus-
tained visual vigilance (0.69) and speeded visual scanning 
(0.65), working memory (0.65), verbal learning (0.81) and 
long-delay verbal free recall (0.78), executive functions 
concerning problem-solving tasks (0.54), verbal inter-
ference (0.75) and set-switching tasks (0.73), immedi-
ate non-verbal memory (0.73), delayed non-verbal recall 
(0.80), visuospatial function (0.55), phonemic (0.51), and 
semantic (0.75) verbal fluency and finally in psychomo-
tor speed (0.66) [11]. Overall, these results suggested that 
patients in a manic or depressed state had significantly 
greater effect size impairment in verbal learning than 
patients in an euthymic state.
The overall evidence suggests that the observed neuro-
cognitive deficit in BD patients is not secondary and does 
not constitute a by-product of mood symptomatology or 
of exposure to medication. This is in spite of the observed 
strong relationship between mood symptoms and neuro-
cognitive impairment. The most probable explanation is 
that neurocognitive impairment reflects a deeper neuro-
biological dysfunction which probably includes the pres-
ence of premorbid developmental abnormalities [324].
The effect of age and age at onset and personal psychiat‑
ric history It has been well established that the overall 
progression of the illness causes and worsens the neuro-
cognitive deterioration. The progression is a concept that 
cannot be easily defined and operationalized; however, 
there are a number of factors and indices which can be 
used to conceptualize it. These factors include the age at 
onset, the duration of illness and the number of previous 
episodes. A general belief is that the neurocognitive func-
tion is strongly associated with the severity of the disease 
[325].
Age The age of the study sample seems to play an impor-
tant role, since young patients with BD have better per-
formance compared to young unipolar patients, but the 
reverse is true in the elderly [326]. Overall, age seems to 
play a complex role. It has been suggested by one meta-
analysis that there is significant impairment of neurocog-
nitive function with advancing age [8], while a second 
one reported that the difference between patients with 
BD and healthy controls attenuates with age, and proba-
bly this happens because the neurocognitive performance 
of healthy people deteriorates with age, at a rate which 
seems to be faster in comparison to what is observed 
in patients with BD [12] thus leading to a floor effect. A 
similar phenomenon has been observed in schizophrenia 
[327–329]. Another meta-analysis reported no effect for 
age [66]
Age at onset The severity of the neurocognitive is cor-
related with age at onset [94, 330], especially in psycho-
motor speed and in verbal memory [9]. The early onset 
of illness and particularly the onset during childhood or 
adolescence is associated with more severe impairment 
[319]. In pediatric BD patients, the observed neurocog-
nitive deficit is similar to the deficit seen in adult BD 
patients [331]. Especially, the impairment in attention is 
correlated with the age at onset [332].
Personal anamnestic During the course of the illness, the 
number of episodes [333], the number of prior hospitali-
zations [137, 188, 333, 334] and the longer duration [333] 
were associated with a worse neurocognitive function. 
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Illness duration is related to the loss of inhibitory con-
trol [197] and to a general memory deficit [175] and ver-
bal memory [149]. Also, worse neurocognitive function 
might be associated with the number of episodes but not 
with the duration of the illness [188, 275]. The impair-
ment in attention is correlated with the age of first hospi-
talization and with the duration of the illness [332].
Some studies found that any history of mood disorder 
has an adverse effect on neurocognition and especially 
on memory [137, 175]. The number of past manic epi-
sodes, hospitalizations, and suicide attempts was corre-
lated with more severe neurocognitive deficit [149]. It has 
been suggested that manic episodes were correlated with 
impairment in verbal learning and memory [144] and in 
attention and executive function [297], while the number 
of past depressive episodes was reported to have adverse 
effect on verbal memory [335] and reaction times [69].
The reverse explanation has also been suggested, with 
the neurocognitive deterioration being the cause rather 
than the effect of worse course and outcome [336]. The 
possibility that neurocognitive differences between psy-
chotic and non-psychotic BD patients are in fact the 
result of an earlier onset of illness or current medica-
tion use rather than a result of psychosis per se cannot 
be excluded. In line with this, it has been reported that 
psychotic BD patients had more hospital admissions, a 
younger age at illness onset, and a larger proportion of 
them were using antipsychotics. They also had less years 
of education [308], which is something that should be 
taken into consideration since it has been suggested 
that education plays a significant moderatory role [11]. 
Finally, two meta-analyses suggested no significant effect 
for age at onset and duration or severity of illness, as 
defined by the number of episodes [9, 66].
The role of  other clinical factors There are many other 
clinical factors which could influence the neurocognitive 
performance of patients with BD. These include brain 
white matter lesions that are sometimes found in remitted 
BD patients and rarely in patients with schizophrenia but 
apparently do not underlie neurocognitive deficits per se 
[337]. Likewise, the lifetime comorbid alcohol use disor-
der, which also does not seem to correlate with the neuro-
cognitive performance at least at earlier stages [316]. One 
study found that overweight and obese BD patients might 
have worse performance on verbal fluency [338].
Education could constitute an additional confounding 
variable, since patients with BD have lower educational 
level despite their IQ level which is comparable with 
that of controls. Thus, controlling for it might attenuate 
the magnitude of the observed neurocognitive impair-
ment [339]. It has been suggested that the neurocognitive 
impairment effect sizes seem to decrease as a function 
of education [8, 12] and shorter duration of education is 
related to a more pronounced deficit in different domains 
such as letter fluency, WCST categories, and the stroop 
test [66]. The explanation might include two arms. The 
first concerns the possibility that education is a marker 
related to the onset and severity of illness, since early and 
severe illness interferes with educational attainment, and 
the second concerns the possibility that education is a 
protective factor per se.
Neurocognitive disorder in BD‑II vs. BD‑I
In spite of the research efforts during the last few dec-
ades, there has not been found a specific neurocognitive 
profile for the different bipolar subtypes [340]. This is 
probably because research on BD-II patients is rare, and 
there are large methodological differences between stud-
ies. As a result, inconclusive data are in place. Research 
on the other subtypes of the bipolar spectrum is essen-
tially lacking. There is only one study reporting data on 
‘bipolar spectrum’ patients. That paper suggested the 
presence of a broad neurocognitive impairment, particu-
larly affecting verbal memory and the executive functions 
[341].
Some unsystematic reports in the literature suggest 
that BD-II patients have similar performance to con-
trols [250, 342, 343], but others supported the notion 
that BD-II patients perform in-between healthy con-
trols and BD-I patients [72, 73, 75, 79, 250, 344–346], 
but this maybe specific concerning verbal memory 
[149, 346] and executive functions [346]. On the con-
trary, there are data suggesting that BD-II patients per-
form similar to BD-I [72, 75, 138, 160], or even perform 
worse than BD-I patients, at least in some specific neu-
rocognitive domains, including reaction time and inhi-
bition [347, 348].
The literature cannot answer the question whether 
there is any qualitative difference between bipolar sub-
types. Such a difference would suggest (although that 
would not be mandatory) that possibly there are differ-
ent neurobiological mechanisms which underlie BD 
subtypes. However, both questions (concerning a quan-
titative and a qualitative difference) remain unanswered. 
For both there are data in favor and against.
A global neurocognitive impairment might be present in 
BD-II patients, with only phonemic verbal fluency being 
preserved and with moderate to strong effect sizes rang-
ing between 0.62 and 1.34 [345]. For premorbid IQ, there 
is only one study which have not found any differences 
between BD-I and BD-II patients, since both groups had 
worse performance in comparison to the performance of 
controls [72]. It has been also shown that the intellectual 
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decline was less pronounced in patients with BD-II in 
comparison to those with BD-I [347, 349]. There are sev-
eral studies suggesting an impairment in psychomotor 
speed and in attention [72, 73, 287, 345, 346, 348]; how-
ever, other studies did not support this [342, 344]. One 
study suggested that reaction time was similar to that 
of controls [350]. Moreover, another study showed that 
attention was intact but psychomotor speed was impaired 
[79]. As far as memory, there seems to be a deficit in verbal 
memory and verbal learning [79, 149, 345–347] but some 
studies disagree [72, 73, 342, 344, 348]. Other authors 
found that in BD-II patients there is a presence of a less 
disorganized semantic system in comparison to patients 
with BD-I [138, 160]. Additionally, delayed memory is 
rather intact [72]. There are controversial data concerning 
the deficit in visual memory, since some authors reported 
an impairment [72, 345, 347] while others disagreed [73, 
287, 342, 343, 348]. Similarly, some authors supported 
the presence of impairment in executive functions and 
in working memory [72, 79, 149, 344–348] while others 
did not [342, 343]. Additionally, there is one study which 
showed that there is a deficit only in working memory but 
not in executive functions [73]. It has been observed that 
all the studies using the stroop color–word test, which 
assesses interference, showed a deficit in inhibitory control 
in BD-II patients [344–347]. Also, there might be a defi-
cit in the emotional processing domain [287, 347]; how-
ever, the emotion recognition seems to be intact [250]. It 
has been also found that unmedicated depressed BD-II 
patients had intact decision-making performance [343]. 
On the other hand, one study suggested that medicated 
BD-II patients had worse performance in comparison to 
unmedicated BD-II patients in sustained attention [287].
One meta-analyses suggested that there is no differ-
ence between BD-II and healthy controls neither in the 
estimated current intelligence quotient (IQ) nor the pre-
morbid IQ [340, 351]. Another meta-analyses found that 
neurocognitive impairment in BD-II patients is as severe 
as in BD-I patients except for the domains of semantic 
fluency and memory [10]. There are contradictory data 
concerning psychomotor speed, verbal and visual mem-
ory and the impairment in these domains is probably 
small in magnitude. On the contrary, there are robust 
data concerning the presence of a working memory defi-
cit and a decrease of cognitive flexibility and impaired 
inhibitory control in BD-II. Patients with BD-II manifest 
a deficit also in recognizing emotions [351]. In quantita-
tive terms, BD-II does not differ much from BD-I [119] 
although it seems that the opinion which prevails is that 
BD-II patients manifest better performance in compari-
son to BD-I but worse than healthy controls and are posi-
tioned in between these two groups.
Long‑term development of the neurocognitive deficit
Methodological issues It is difficult to chart the long-
term course of BD since there are no reliable indices to 
describe and chart the course in a global way. This hap-
pens because BD is a complex illness with different phases 
and clinical characters. Moreover, there is no clear direc-
tion of causality. One possibility is that the accumulation 
of mood episodes impacts negatively the neurocognitive 
function; however, the reverse is equally possible. A third 
possibility is that both the neurocognitive deficit and 
mood symptoms, independently from each other, reflect 
a specific pattern of clinical course and disease phenotype 
without any direct relationship to each other.
Premorbid period Patients with BD have a relatively 
intact neurocognitive functioning throughout childhood 
and adolescence, and the neurocognitive impairment 
emerges only after the overt symptom onset, and this is 
in contrast to what is known concerning patients with 
schizophrenia [352]. In accord with this, it has been found 
that children who later develop BD exhibit good academic 
functioning prior to illness onset [32, 353–356].
However, some studies argue for the opposite. A pro-
spective investigation of executive functioning in at-risk 
adolescents showed an impairment in executive function 
in those who later developed BD [357]. Also, an increased 
prevalence of abnormal developmental history has been 
shown with delayed language acquisition, and motor 
and social development in a group of adolescents with 
BD [358]. A large Finnish cohort study which evaluated 
verbal, arithmetic and visuospatial reasoning in healthy 
male conscripts (mean age 19.9  years) showed that the 
premorbid visuospatial impairment was associated with 
later development of both BD and schizophrenia [359]. 
Also, another prospective study from Sweden suggested 
that 7 % of 56 adolescents with developmental deficits at 
the age of 6 years, went on to develop BD, compared with 
none from the control group [360].
Early stages of BD The neurocognitive maturation and 
the development of the child is probably adversely affected 
by the development of BD during childhood [361]. Gener-
ally, the overall neuropsychological deficit has been asso-
ciated with earlier age at onset which, however, is unclear 
to which extend it represents simply a longer duration 
[330]. Immediately following illness onset, adolescents 
with BD exhibit poor performance in social and neuro-
cognitive domains [353]. Similarly, in adults, the impair-
ment is present already during the first mood episode 
[301]. At illness onset, there is a deficit in many domains 
such as sustained attention [97], spatial/non-verbal rea-
soning, learning and recall, and several aspects of execu-
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tive function [362] as well as memory, verbal fluency and 
executive function [121].
Medium stages of BD Patients with two or more illness 
episodes manifest poorer performance than patients with 
just one episode [275] and within 1–3 years, a significant 
further deterioration in the executive function can be 
observed [363], which along with processing speed are 
considered to be the main long-term neurocognitive defi-
cits in BD [364]. One study found that the rest neurocog-
nitive functions seem to be stable at 1–3-year follow-up 
[363, 365]. However, the complete picture of the results 
is controversial concerning the short-term deterioration 
[53, 147, 151, 153, 192, 334].
Latter in the course of the illness, repeated acute epi-
sodes negatively impact the neurocognitive functioning 
[352], which seems to correlate with both the number of 
affective episodes and the overall duration of illness [81, 
97, 108, 144, 333, 366]. In turn, duration of illness and dis-
ease course are reported to correlate with verbal and vis-
ual memory and executive function [102, 108, 367]. The 
comparison of young, elderly, and chronic BD patients 
revealed that a greater number of chronic patients scored 
in the severely impaired range on a memory and execu-
tive battery than their counterparts with fewer past epi-
sodes [318]. Thus, it is possible that, instead of reflecting 
long-term damage to the brain because of repeated acute 
episodes, poor neurocognitive performance in multi-epi-
sode patients may be the result of the presence of chronic 
residual mood symptoms. It is known that BD patients 
experience mood liability [368, 369] and residual symp-
toms, usually depressive, during periods of euthymia in 
spite of the fact that they were rated as euthymic by clini-
cians [162].
Later stages of BD Complex comorbidity is frequent in 
chronic patients and it is often accompanied with incom-
plete remission. Thus, the length of BD could act as a con-
founding factor in patients with comorbidity, e.g., with 
alcohol dependence in comparison to a non-alcoholic 
group [151]. A weak point in the literature is that although 
the acute effects of alcohol or drug intoxication have been 
controlled for in some studies [147, 176, 337], the effect of 
past exposures has not been taken into account.
Continuous medication treatment is also a confounding 
variable especially at later stages and when chronicity and 
complex comorbidity is in place. For example, although 
one study reported that there has not been observed fur-
ther decline of neurocognitive function in patients under 
long-term lithium treatment [276], another study sug-
gested that the executive function deficit was negatively 
correlated with years of exposure to antipsychotic drugs 
[108]. This latter finding could reflect either a toxic effect 
of long-term antipsychotic medication, the toxic effect of 
chronic psychosis or both.
In the long term, the neurocognitive deficit seems to be 
associated with the functional outcome. This relationship 
is particularly true for processing speed, attention, mem-
ory [370] as well as the visual/motor processing domain 
[371]. One study used cross-sectional data from a large 
case-register study of 14,000 people which were hospital-
ized with a mood disorder, 81,380 patients with osteo-
arthritis and 69,149 patients with diabetes. The results 
indicated that patients with BD have a 6  % increase in 
the risk of dementia with every episode leading to admis-
sion and overall this risk was higher in comparison to 
the two control groups [372, 373]. Although these data 
are in favor of a neurodegenerative process, it is also 
possible that the findings reflect different courses of the 
illness plus a different probability of long-term medica-
tion treatment and electroconvulsive therapy (ECT) with 
unknown long-term effects [123]. This effect has already 
been discussed since patients with more severe and fre-
quent affective episodes perform more poorly on neuro-
cognitive testing [333].
In accord with this, a course characterized by chro-
nicity and residual symptoms with lack of remission 
between episodes is related to a progressive neurocogni-
tive deficit and in this frame an important role is attrib-
uted to the specific clinical course of BD [318, 333]. As 
previously mentioned, there is a deleterious effect of psy-
chotic symptoms that have deleterious effects [352] and 
as already previously mentioned antipsychotic medica-
tion is associated with poorer performance on IQ, mem-
ory and working memory assessments [46].
The overall longitudinal course suggests that neurode-
velopmental factors play a minor role in the emergence 
of neuropsychological dysfunction in BD [324, 352]. 
Psychopathological factors during the course of the dis-
order itself are probably related to the neurocognitive 
impairment, but the nature of this association remains 
unknown. A graphical representation of the long-term 
development of the neurocognitive deficit in BD patients 
in comparison to schizophrenia and normal controls is 
shown in Fig. 2.
Awareness of the neurocognitive deficit
Although many patients with BD frequently complain 
about neurocognitive problems in attention, concen-
tration and memory, there are limited data on the rela-
tionship between subjective cognitive complaints with 
objective neuropsychological deficits.
The patients’ subjective cognitive complaints do not 
seem to correlate or predict objective neuropsychologi-
cal deficits [142, 164, 374]. One study has suggested that 
there might be a weak correlation between subjective 
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complains and deficits in attention, memory and execute 
function [375]. Moreover, it has been shown that neither 
mood symptoms nor the severity of mania or depres-
sion correlate with patients’ self-report [142] One study 
reported that patients with BD might show more subjec-
tive complaints when there is a higher number of epi-
sodes, and especially a higher number of mixed episodes, 
a longer duration of the illness and when the onset of the 
illness occurred at an earlier age [375]. There seems to be 
some association between depressive symptoms and self-
report neurocognitive complaints; however, the associa-
tion between complaints and objective neurocognitive 
functioning is not moderated by mood symptoms [374].
Gender and the neurocognitive deficit
There is limited literature concerning the role that gender 
might play and no conclusions can be derived. Males with 
BD manifest a more severe deficit in immediate memory 
[376] and executive function [126] whilst one study sug-
gested that gender does not play any role on emotion 
recognition [250]. A better memory performance might 
be related with female gender [175], while another study 
suggested that the verbal memory deficit might relate to 
female gender as an endophenotype [377]. Overall, the 
data are conflicting with one out of three recent meta-
analysis being in favor of a gender effect [8], while the 
two others were against [12, 66].
The neurocognitive deficit as an endophenotype for BD
Endophenotype constitutes a stable pattern of behav-
ioral symptoms with a clear genetic connection. It can 
be used to bridge the gap between high-level symptom 
presentation and low-level genetic variability. Ideally, an 
endophenotype might be useful in the differential diag-
nosis between disorders when they present with similar 
symptoms. Additionally, an endophenotype is associated 
with a specific disorder in the population, and should be 
heritable and state-independent. It is expected that endo-
phenotype and the specific diagnosis co-segregate within 
families and the endophenotype is found in non-affected 
family members at a higher rate than in the general 
population.
The neurocognitive impairment in patients with BD 
is at least partially different in comparison to the deficit 
seen in patients with schizophrenia and it is also at least 
partially state-independent and definitely present during 
periods of complete recovery and euthymia. Although 
the literature so far does not support the use of global 
measures of neurocognition as endophenotypes [378–
380]. On the other hand, however, specific neurocogni-
tive deficits might be relevant, although further research 
is needed. It has been reported that inaffective relatives 
of patients occupy an intermediate position between 
patients and healthy controls concerning specific neuro-
cognitive functions [195].
Twin studies There is not much data concerning dis-
cordant monozygotic or dizygotic twins. Healthy co-twins 
performance in aspects of concentration, verbal and vis-
ual memory and verbal recognition and executive func-
tion is worse than controls [381], although a population-
based study reported that the verbal memory deficit as an 
endophenotype might relate to female gender alone [377]. 
It has been also reported that neither BD patients nor 
their unaffected co-twins differed from control subjects 
in spatial working memory [171]. Another population-
based study on healthy monozygotic and dizygotic twins 
showed that monozygotic high-risk twins manifested a 
significant deficit on selective and sustained attention, 
executive function, language processing and working and 
declarative memory, while the dizygotic high-risk twins 
manifested lower scores only on language processing and 
episodic memory [382]. No deficit was found on response 
inhibition in discordant twins of BD patients (event with 
a psychotic or familial form). Lower performance in twins 
during testing could be explained by current depressive 
symptoms [383]. It is interesting than in most of these 
studies, the unaffected co-twins suffered from minor or 
subthreshold mental disorders and dysthymia. Overall, 
twin studies provide some but not strong evidence for the 
presence of an endophenotype on the basis of neurocog-
nitive impairment.
Studies on first‑degree relatives There are a limited num-
ber of studies in children whose parents suffer from BD. 
Fig. 2 Long-term evolution of the neurocognitive deficit in BD 
patients, in comparison to patients with schizophrenia and normal 
subjects. Overall, in contrast to schizophrenia patients, BD patients 
exhibit a relatively intact neurocognitive functioning throughout 
childhood and adolescence, and the neurocognitive deterioration 
is observed only after the overt symptom onset. Reproduced after 
permission from Lewandowski et al. [352]
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They suggest that high-risk children differ from control 
children in terms of reaction time; however, the quality 
data are rather low [384]. The same research group also 
reported that both high-risk and control children have 
similar performance in speech competence tests [385]. 
In two other studies, high-risk children were impaired in 
PIQ but not in VIQ; however, half of them were suffer-
ing from depression [28, 386]. Another study found that 
high-risk children and controls had similar IQ; however, 
controls had better performance in some reading and 
arithmetic cognitive tasks and there was an increased 
rate of VIQ-PIQ discrepancy [387]. A study on visual 
backward masking was also negative [69]. High-risk rela-
tives had slower reaction time on a sustained auditory 
attention task [388]. Moreover, it has been shown by a 
recent study that specific executive functions which are 
supposedly located in the ventral frontal cortex might be 
impaired in high-risk children in comparison to controls 
[389]. Also, there might be a deficit in healthy high-risk 
children in spatial memory, in attention and in executive 
functions, even after correction for multiple confound-
ing factors [390]. Overall, these studies provide evidence 
for the usefulness of executive function impairment as an 
endophenotype for BD.
Studies on  mixed samples of  relatives There are more 
data concerning families of BD patients. These studies uti-
lized mixed samples of first- and second-degree patients.
One study which utilized only female relatives of 
patients (most of them psychotic) reported that their 
IQ was superior to the IQ of controls. Also, it argued in 
favor of the usefulness of visual memory and executive 
function as endophenotypes [380]. Another study indi-
cated that IQ was similar to controls [30] while on the 
contrary, another one reported the presence of a general 
and non-specific deficit in IQ, with some pronounced 
effect on verbal fluency [59]. More recent data suggest a 
higher discrepancy between VIQ and PIQ in families of 
patients with BD in comparison to healthy controls; how-
ever, these results were inconsistent with previous find-
ings of higher VIQ in comparison to PIQ [356].
A deficit in psychomotor speed is also reported [52, 70, 
143, 391], and while studies suggested an impairment in 
concentration [392], others have found that the impair-
ment concerns shifting, but not sustaining attention 
(concentration) [98, 393, 394]. One study found a defi-
cit in delayed recall in well-educated siblings with high 
IQ [395]. The literature also suggests the presence of an 
impairment in concentration, in the visuospatial declara-
tive memory [392], in verbal working memory [396], and 
verbal [70, 143, 391, 397], visual [195] and auditory verbal 
learning [398] in working memory [399] and in executive 
function domain [52, 70, 143, 391, 396, 400].
There is one report on increased emotional interfer-
ence with a bias towards mood-related information [401]. 
At-risk youths make more errors when identifying facial 
emotions, and the magnitude of the deficit was simi-
lar to that observed in patients with BD [243]; however, 
another study reported no deficit either in BD patients or 
in their first-degree relatives [257].
It is interesting that in spite of an overall normal neu-
rocognitive functioning, there might be present some 
kind of subtle impairment in first-degree relatives of 
BD patients. A study which utilized l-tryptophan chal-
lenge showed that under challenge, a deficit emerges 
in relatives of BD patients in comparison to controls in 
memory, focused and divided attention, and psychomo-
tor performance. Additionally, the relatives of patients 
with BD-I performed worse than the relatives of BD-II 
patients [402, 403].
Reviews and meta‑analyses Overall, the literature sup-
ports the idea that the deficit in executive function could 
constitute an endophenotype for BD, especially con-
cerning psychotic cases. However, there are some data, 
which dispute the usefulness of specific executive func-
tions, including cognitive control during episodic mem-
ory retrieval [397], response inhibition [383] and cogni-
tive set-shifting [393]. Also, while a widespread deficit in 
attention and memory in families of patients with BD is 
reported, there are some negative data concerning con-
centration [98], psychomotor performance [396, 400], 
working memory [393], spatial working memory [171], 
verbal learning [391], verbal memory [396] and executive 
functions [400]. It is almost certain that IQ cannot serve 
as an endophenotype of the illness.
Reviews and meta-analyses suggest that the executive 
function and the verbal memory deficit could serve as 
core endophenotypes for BD [8, 367, 404], but conclu-
sions are premature. The effect sizes reported are 0.49 
with the stroop test and 0.37 with the TMT-B, while 
concerning immediate verbal memory the effect size is 
0.42. Thus, in first-degree relatives, effect sizes were small 
(d < 0.5), but significantly different from healthy controls 
in particular concerning executive function and verbal 
memory [8].
In line with the above, another meta-analysis reported 
small effect sizes, that is, 0.20 for current IQ, 0.18–0.36 
for attention and 0.17–0.22 for mental speed, 0.13–0.33 
for various aspects of memory, 0.27 for verbal fluency 
and 0.24–0.51 for executive functions with the effect for 
the stroop test being the highest (0.51). This meta-ana-
lytic study demonstrated that impaired response inhibi-
tion might constitute the most prominent neurocognitive 
endophenotype of BD. Another executive measure, set-
shifting (TMT-B, 0.38; WCST perseveration, 0.36) and 
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two other neurocognitive domains, verbal memory 
(0.27–0.33) and sustained attention (0.36) also met the 
criteria as potential endophenotypes of BD. These results 
suggest that the response inhibition deficit, a potential 
marker of ventral prefrontal dysfunction, seems to be the 
most prominent endophenotype of BD [9].
In Table  2, the effect sizes of neurocognitive impair-
ment in relatives of BD patients are shown. These effect 
sizes determine whether a specific impairment is of suf-
ficient magnitude to be considered as an endophenotype.
Discussion
Many areas of the neurocognitive function of BD still 
remain uncharted. It seems that a little less than half of 
BD patients suffer from a significant neurocognitive defi-
cit and although the majority of BD patients might not 
differ from healthy controls, it is also true that some oth-
ers do not differ from patients with schizophrenia. Both 
patient groups share a similar cognitive impairment pro-
file with different degrees of deficits and thus the differ-
ence between them seems to be more quantitative rather 
than qualitative [405].
The complexity of the illness is evident also in the 
patients’ neurocognitive function and its assessment. 
The core deficit, which constitutes a direct consequence 
of the disease itself, seems to be independent not only 
from the other components of the disease but also from 
mood symptoms. This core deficit is either increased or 
on the contrary it is attenuated by many factors such as 
the disease phase, specific personal characteristics of the 
patients (age, gender, education, etc.), current symptom-
atology and its treatment and the long-term course and 
the long-term exposure to medication, psychiatric and 
somatic comorbidity and alcohol and/or substance abuse.
However, the origin and the etiopathogenesis of the 
core neurocognitive impairment remains elusive. Prob-
ably, there is a neurodegenerative component as a con-
sequence of repeated mood episodes and psychotic 
features. Additionally, the effect of chronicity is quite 
strong while the neurodevelopmental component is 
either absent or very weak. This probably differentiates 
BD from schizophrenia, in which the neurodevelop-
mental component is strong. Such a neurodevelopmen-
tal effect is evident in some but not all patients with BP. 
A model suggesting that only BD patients who share 
common genetic risk factors with schizophrenia have 
premorbid neurodevelopmental neurocognitive defi-
cits has been proposed [406]. On the other hand, there 
is no consistent evidence supporting that BD, as a group 
of disorders, have a progressively deteriorating course of 
neurocognitive functions [407].
Overall, the neurocognitive deficit concerns almost all 
domains with only a few exceptions and its magnitude is 
at the severe range during the acute episodes and at the 
medium range during euthymia. A summary of effect 
sizes by neurocognitive domain and illness phase is 
shown in Table 2.
There seems to be a small to moderate reduction in 
current IQ and general neurocognitive function dur-
ing all phases of the illness; however, premorbid IQ and 
general neurocognitive function seems to be intact. 
Impairments in verbal memory, attention, and executive 
functions tend to be present during and after the first epi-
sode. Preliminary evidence suggests that these deficits in 
specific neurocognitive domains might precede the onset 
of illness [408]. The pattern and the severity of the neu-
ropsychological impairment seems to be in place already 
during the first mood episode and these patients seem to 
lie intermediate between patients with a first episode of 
schizophrenia and healthy controls [409]
There is an impairment in psychomotor speed, atten-
tion, working memory and most of the verbal and some 
non-verbal components of memory as well as verbal flu-
ency, executive functions and social cognition which 
is typically severe during the acute phases and moder-
ate during euthymia. BD, irrespective of illness phase, 
is characterized by a deficit in the acquisition of new 
information, but not in retention, probably because of a 
disruption in the engagement of effortful processes. An 
important exception is the deficit in visuospatial skills 
which is present only during the acute phases and not 
during euthymia. An important methodological prob-
lem is that different studies utilize different definitions of 
euthymia and as a result, it is unclear whether subthresh-
old residual symptoms are present or not, what their 
polarity is and whether they are responsible for the defi-
cit which is observed during remission.
The overall negative impact of medication is small 
and it is confounded by the specific clinical symptoms, 
for which medication is used for their treatment. This is 
especially true concerning antipsychotics and psychotic 
symptoms.
Although the prevailing opinion is that BD-II patients 
perform better than BD-I but worse than healthy con-
trols, the literature has shown that in quantitative terms, 
BD-II does not differ much from BD-I.
The specific clinical course of the illness seems to play 
an important role. A course characterized by residual 
symptoms, chronicity and lack of remission between epi-
sodes is related to a progressive neurocognitive deficit. Of 
significant importance is the adverse effect specifically of 
psychotic symptoms, while manic episodes seem to affect 
neurocognitive function more than depressive episodes 
do. Age, age at onset, duration of the illness and num-
ber of episodes, not only reflect distinct but overlapping 
aspects of the overall disease burden but also are related 
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to the neurocognitive impairment and its progression. 
However, the data are inconclusive concerning the mag-
nitude and the true nature of this relationship.
The verbal memory and the executive function defi-
cit could be the central endophenotypes of the illness. 
The most prominent endophenotype of BD seems to be 
the response inhibition deficit. However, in most family 
studies, unaffected at-risk family members who do not 
suffer from BD but they do manifest dysthymic or other, 
often subthreshold mood states, often in the form of 
temperament, and this might again act as a confounding 
variable.
Conclusions
In conclusion, the literature suggests that the neurocog-
nitive deficit in BD patients concerns almost all domains 
with only a few exceptions. Its magnitude is at the severe 
range during the acute episodes and at the medium range 
during euthymia, while the origin of the deficit remains 
unclear. In terms of neurocognitive function, BD patients 
do quantitatively better than patients with schizophre-
nia but the qualitative pattern of the deficit is similar in 
the two disorders. There are no clear differences between 
BD subtypes. The deficit is present early in the course of 
the disorder. At least in some patients, it might emerge 
before the onset of the first mood episode and in the 
majority of patients it progresses probably in relationship 
with the manifestation of psychotic symptoms. The ver-
bal memory and the executive function deficit probably 
constitute endophenotypes, while the role of medication 
as a causative factor is limited.
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